Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 15-Oct-24 9:16 AM View:  | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 14-Oct-24 | Option Exercise | 3,290 | $9.57 | $31,485.30 | 13% 24.59K to 27.88K | |
| 15-Oct-24 9:16 AM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 14-Oct-24 | Planned Option Sale | 3,290 | $25.00 | $82,250.00 | (12%) 27.88K to 24.59K | |
| 01-Oct-24 7:36 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 01-Oct-24 | Option Exercise | 5,760 | $1.86 | $10,713.60 | 23% 24.59K to 30.35K | |
| 01-Oct-24 7:36 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 01-Oct-24 | Planned Option Sale | 5,760 | $22.23 | $128,017.00 | (19%) 30.35K to 24.59K | |
| 03-Sep-24 5:33 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 03-Sep-24 | Planned Option Sale | 9,050 | $24.94 | $225,736.00 | (27%) 33.64K to 24.59K | |
| 03-Sep-24 5:33 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 03-Sep-24 | Option Exercise | 9,050 | $4.66 | $42,198.90 | 37% 24.59K to 33.64K | |
| 26-Aug-24 6:23 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 26-Aug-24 | Option Exercise | 9,870 | $6.08 | $60,046.20 | 40% 24.59K to 34.46K | |
| 26-Aug-24 5:41 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 26-Aug-24 | Sale (Planned) | 20,000 | $25.22 | $504,370.00 | (39%) 51.0K to 31.0K | |
| 26-Aug-24 6:23 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 26-Aug-24 | Planned Option Sale | 9,870 | $25.01 | $246,843.00 | (29%) 34.46K to 24.59K | |
| 01-Aug-24 7:06 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 01-Aug-24 | Planned Option Sale | 5,760 | $21.43 | $123,459.00 | (19%) 30.35K to 24.59K | |
| 01-Aug-24 7:06 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 01-Aug-24 | Sale (Planned) | 3,477 | $21.45 | $74,575.90 | (6%) 54.48K to 51.0K | |
| 01-Aug-24 7:06 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 01-Aug-24 | Option Exercise | 5,760 | $1.86 | $10,713.60 | 23% 24.59K to 30.35K | |
| 30-Jul-24 7:06 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jul-24 | Option Exercise | 8,636 | -- | -- | 18% 48.33K to 56.97K | |
| 30-Jul-24 7:06 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jul-24 | Option Exercise | 7,674 | -- | -- | 39% 19.84K to 27.51K | |
| 30-Jul-24 7:06 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jul-24 | Option Exercise | 8,957 | -- | -- | 23% 39.6K to 48.56K | |
| 30-Jul-24 7:06 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jul-24 | Option Sale | 3,408 | $20.67 | $70,435.50 | (7%) 48.56K to 45.15K | |
| 30-Jul-24 7:06 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jul-24 | Option Sale | 2,920 | $20.67 | $60,349.70 | (11%) 27.51K to 24.59K | |
| 30-Jul-24 7:06 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jul-24 | Option Sale | 2,490 | $20.67 | $51,462.60 | (4%) 56.97K to 54.48K | |
| 18-Jul-24 4:06 PM View: | Kunkel Lori Anne Director | Nurix Therapeutics, Inc. (NRIX) | 17-Jul-24 | Gift | 54,027 | -- | -- | (100%) 54.03K to 0 | |
| 01-Jul-24 6:35 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 01-Jul-24 | Planned Option Sale | 5,760 | $20.81 | $119,837.00 | (23%) 25.6K to 19.84K | |
| 01-Jul-24 6:35 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 01-Jul-24 | Option Exercise | 5,760 | $1.86 | $10,713.60 | 29% 19.84K to 25.6K | |
| 20-Jun-24 4:58 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 20-Jun-24 | Sale (Planned) | 20,000 | $20.01 | $400,216.00 | (29%) 68.33K to 48.33K | |
| 13-Jun-24 6:39 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 13-Jun-24 | Option Exercise | 1,864 | $1.86 | $3,467.04 | 9% 19.84K to 21.7K | |
| 13-Jun-24 6:39 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 13-Jun-24 | Planned Option Sale | 1,864 | $17.02 | $31,721.20 | (9%) 21.7K to 19.84K | |
| 12-Jun-24 7:30 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 12-Jun-24 | Option Exercise | 1,900 | $1.86 | $3,534.00 | 10% 19.84K to 21.74K | |
| 12-Jun-24 7:30 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 12-Jun-24 | Planned Option Sale | 1,900 | $17.01 | $32,319.00 | (9%) 21.74K to 19.84K | |
| 05-Jun-24 6:01 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 05-Jun-24 | Planned Option Sale | 400 | $17.00 | $6,801.00 | (2%) 20.24K to 19.84K | |
| 05-Jun-24 6:01 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 05-Jun-24 | Option Exercise | 400 | $1.86 | $744.00 | 2% 19.84K to 20.24K | |
| 03-Jun-24 6:36 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 03-Jun-24 | Option Exercise | 1,596 | $1.86 | $2,968.56 | 8% 19.84K to 21.43K | |
| 03-Jun-24 6:36 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 03-Jun-24 | Planned Option Sale | 1,596 | $17.01 | $27,152.90 | (7%) 21.43K to 19.84K | |
| 02-May-24 6:01 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 02-May-24 | Sale (Planned) | 3,499 | $12.83 | $44,878.20 | (5%) 71.83K to 68.33K | |
| 30-Apr-24 6:33 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Apr-24 | Option Sale | 1,513 | $12.04 | $18,219.80 | (7%) 21.35K to 19.84K | |
| 30-Apr-24 6:33 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Apr-24 | Option Exercise | 5,206 | -- | -- | 14% 36.4K to 41.61K | |
| 30-Apr-24 6:33 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Apr-24 | Option Sale | 1,387 | $12.04 | $16,702.50 | (2%) 73.22K to 71.83K | |
| 30-Apr-24 6:33 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Apr-24 | Option Exercise | 3,924 | -- | -- | 23% 17.43K to 21.35K | |
| 30-Apr-24 6:33 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Apr-24 | Option Exercise | 4,886 | -- | -- | 7% 68.33K to 73.22K | |
| 30-Apr-24 6:33 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Apr-24 | Option Sale | 2,007 | $12.04 | $24,168.70 | (5%) 41.61K to 39.6K | |
| 16-Feb-24 7:20 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 16-Feb-24 | Sale (Planned) | 6,812 | $10.02 | $68,222.90 | (9%) 75.14K to 68.33K | |
| 30-Jan-24 6:52 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jan-24 | Option Exercise | 3,924 | -- | -- | 26% 15.26K to 19.19K | |
| 30-Jan-24 6:53 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jan-24 | Option Exercise | 4,886 | -- | -- | 7% 71.93K to 76.82K | |
| 30-Jan-24 6:52 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jan-24 | Option Sale | 2,334 | $7.99 | $18,649.10 | (6%) 38.74K to 36.4K | |
| 30-Jan-24 6:53 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jan-24 | Option Sale | 1,671 | $7.99 | $13,351.60 | (2%) 76.82K to 75.14K | |
| 30-Jan-24 6:52 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jan-24 | Option Sale | 1,760 | $7.99 | $14,062.80 | (9%) 19.19K to 17.43K | |
| 30-Jan-24 6:52 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Jan-24 | Option Exercise | 5,207 | -- | -- | 16% 33.53K to 38.74K | |
| 21-Dec-23 5:19 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 20-Dec-23 | Sale (Planned) | 3,541 | $10.00 | $35,421.00 | (5%) 75.47K to 71.93K | |
| 20-Dec-23 4:55 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 19-Dec-23 | Sale (Planned) | 10,906 | $10.00 | $109,093.00 | (13%) 86.38K to 75.47K | |
| 01-Nov-23 4:40 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 31-Oct-23 | Option Sale | 1,633 | $5.20 | $8,487.35 | (5%) 35.16K to 33.53K | |
| 01-Nov-23 4:40 PM View: | Ring Christine Chief Legal Officer | Nurix Therapeutics, Inc. (NRIX) | 31-Oct-23 | Option Sale | 1,232 | $5.20 | $6,403.20 | (7%) 16.5K to 15.26K | |
| 01-Nov-23 4:41 PM View: | van Houte Hans Chief Financial Officer | Nurix Therapeutics, Inc. (NRIX) | 31-Oct-23 | Option Sale | 1,080 | $5.20 | $5,613.19 | (1%) 87.46K to 86.38K | |
| 01-Nov-23 4:40 PM View: | Hansen Gwenn Chief Scientific Officer | Nurix Therapeutics, Inc. (NRIX) | 30-Oct-23 | Option Exercise | 5,207 | -- | -- | 17% 29.95K to 35.16K |
